<DOC>
	<DOCNO>NCT00624702</DOCNO>
	<brief_summary>This study explore information whether change salt formulation indacaterol affect incidence post-inhalation cough .</brief_summary>
	<brief_title>Tolerability Indacaterol Salts ( Maleate , Xinafoate Acetate ) Comparison Placebo Patients With Mild Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male female patient 18 65 year old ( inclusive ) Patients mild moderate persistent asthma BMI must within range 1832 kg/m2 inclusive Female subject must : 1. sterilize least 6 month prior screen 2. postmenopausal regular bleeding least year prior inclusion Patients lifethreatening arrhythmias Patients COPD diabetes mellitus History immunocompromise , include positive HIV A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Asthma , cough , spirometry , maleate , xinafoate , acetate , SDDPI ( single dose dry powder inhaler )</keyword>
</DOC>